BUZZ-BioAge Labs edges down after stock sale hiked to $115 mln
I'm PortAI, I can summarize articles.
BioAge Labsshares fell 0.3% to $20.06 after the company raised $115 million by selling approximately 5.9 million shares at $19.50, a 3.1% discount to the last close. The funds will support research and development of its product candidates, including BGE-102 for cardiovascular and retinal diseases. Despite a recent drop, BIOA shares have surged 52% in early 2026 and tripled in the last three months. Analysts have mixed ratings, with one 'strong buy' and three 'hold' recommendations, targeting prices of $9, $12, and $15.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments